Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four antibiotics used for treating various bacterial infections: - **Ciprofloxacin**: A fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. - **Trimethoprim**: An antifolate medication that inhibits dihydrofolate reductase, interfering with bacterial folate synthesis. - **Sulfamethoxazole**: A sulfonamide antibiotic that inhibits dihydropteroate synthase, also interfering with bacterial folate synthesis. Often used in combination with trimethoprim (as co-trimoxazole or TMP-SMX). - **Ertapenem**: A carbapenem antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins. This combination would provide extremely broad-spectrum coverage against Gram-positive, Gram-negative, and anaerobic bacteria, including many drug-resistant strains. It would typically be used for severe, complex, or polymicrobial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciprofloxacin + trimethoprim + sulfamethoxazole + ertapenem.